Cell reports. Medicine · 2022

Immunogenicity and reactogenicity of heterologous immunization against SARS CoV-2 using Sputnik V, ChAdOx1-S, BBIBP-CorV, Ad5-nCoV, and mRNA-1273.

СтатьяПоддержка исследования: вне правительства СШАПоддержка NIH: внешняя программаНазвание и аннотация: Перевод в очереди

Обработка статьи · этапы, ошибки и управление

Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Pascuale Carla A, Varese Augusto, Ojeda Diego S, Pasinovich Marina E, Lopez Laura, Rossi Andres H, Rodriguez Pamela E, Miglietta Esteban A, Laboratorio SeVa Group, Mazzitelli Ignacio, Di Diego Garcia Facundo, Sanchez Lautaro, Rouco Santiago Oviedo, Gonzalez Lopez Ledesma María Mora, Zurano Juan Pablo, Mazzitelli Bianca, Scruzzi Graciela, Barbero Paula, Cardozo Diego, Gallego Sandra, Borda Mariel, Diaz Miguel, Ministerio de Salud de la Provincia de Córdoba Group, UNC-Fac. Cs. Médicas-InViV Group, Ridao Francisco, Rosales Angela Brigido, Ministerio de Salud de la Provincia de La Rioja Group, Bhon Jorge, Talia Juan M, Diangelo María E, Lacaze María A, Ministerio de Salud de la Provincia de San Luis Group, Aime Balanzino, Gutierrez Sebastian Isaac, Ercole Regina, Toro Rosana, Tau Lorena, Delaplace Laura, Compagnucci Malena Ferreyra, Universidad Nacional de La Plata Group, Sartori Celeste, Desimone Isabel, Echegoyen Cecilia, Velazquez Pilar, Testa Clarisa, Ministerio de Salud de la Provincia de Buenos Aires Group, Hozbor Daniela, Docena Guillermo, Laino Carlos H, Kreplak Nicolas, Pifano Marina, Barbas Gabriela, Rearte Analía, Vizzotti Carla, Castelli Juan M, Geffner Jorge, Gamarnik Andrea V

Аннотация

Heterologous vaccination against coronavirus disease 2019 (COVID-19) provides a rational strategy to rapidly increase vaccination coverage in many regions of the world. Although data regarding messenger RNA (mRNA) and ChAdOx1 vaccine combinations are available, there is limited information about the combination of these platforms with other vaccines widely used in developing countries, such as BBIBP-CorV and Sputnik V. Here, we assess the immunogenicity and reactogenicity of 15 vaccine combinations in 1,314 participants. We evaluate immunoglobulin G (IgG) anti-spike response and virus neutralizing titers and observe that a number of heterologous vaccine combinations are equivalent or superior to homologous schemes. For all cohorts in this study, the highest antibody response is induced by mRNA-1273 as the second dose. No serious adverse events are detected in any of the schedules analyzed. Our observations provide rational support for the use of different vaccine combinations to achieve wide vaccine coverage in the shortest possible time.

Предметные рубрики MeSH

2019-nCoV Vaccine mRNA-1273 Antibodies, Viral COVID-19 Humans Immunization RNA, Messenger SARS-CoV-2 Vaccination Viral Vaccines

Immunogenicity and reactogenicity of heterologous immunization against SARS CoV-2 using Sputnik V, ChAdOx1-S, BBIBP-CorV, Ad5-nCoV, and mRNA-1273.

Ошибки и ограничения

Аннотация

Предметные рубрики MeSH